HC Wainwright & Co. Maintains Buy Rating and $37.00 Price Target on SpyGlass Pharma
HC Wainwright & Co. has reaffirmed its positive outlook on SpyGlass Pharma, maintaining a 'Buy' rating and a $37.00 price target for the company's shares.
Stocks · News reference
SpyGlass Pharma Announces Trial Results From Bimatoprost Drug Pad-IOL System In Participants With Mild-To-Moderate Open Angle Glaucoma Reduces Mean IOP By 37% Across All Three Dose Cohorts; 86% Participants Remained Off All Topical IOP-Lowering Drops
SpyGlass Pharma, Inc. (Nasdaq: SGP) ("SpyGlass Pharma" or "Company"), a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
HC Wainwright & Co. Reiterates Buy on SpyGlass Pharma, Maintains $37 Price Target
HC Wainwright & Co. analyst Yi Chen reiterates SpyGlass Pharma (NASDAQ:SGP) with a Buy and maintains $37 price target.
8-K filing — SpyGlass Pharma, Inc. (SGP)
Filed: 2026-10-19 AccNo: 0001778922-26-000052 Size: 213 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits